Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for
METASTATIC FOR COLORECTAL CANCER
On May 8, 2017, Array BioPharma and Merck announced entering into a clinical trial collaboration to investigate the safety and efficacy of Array's MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, Keytruda® (pembrolizumab), in metastatic colorectal cancer patients with microsatellite stable tumors (MSS CRC).
The decision on this collaboration was based on the growing body of preclinical and clinical evidence . . .
This content is for paid subscribers.
Today’s Highlights July 10, 2017